Champion Chatter – what costs more than £500,000 per gram?
News today includes fantastic results from a highly unusual small cap and a cracking load of old waffle to describe a profit warning. Read on....
Bioventix (AIM:BVXP) UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics Mkt cap £154n – shares down 6% on the day Audited (not preliminary) results for the year ended 30 June 2018. Congratulations to Bioventix for the timely reporting of their audited financial statements. The highlights make great reading: Revenue up 21% to £8.8m - revenue benefitted from a back royalty of £0.8m, notwithstanding it’s still excellent growth. Profit before tax up 19% to £6.9m – not often that you see a 78% pre-tax margin! Cash up £0.8m to £7.0m, even…